MENU
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  • About Us
  • Blog
  • Series
  • Category
  • Contact Us
  • 日本語
  • English
Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~
  • About Us
    • Profile
  • Blog
    • Comment Policy
  • Series
    • Bispecific Antibody
    • ADC
    • CAR-T
    • KRAS Deep Dive
    • Oncology Approvals
  • Category
  • Contact Us
  • 日本語
  • English
  1. Home
  2. gene editing

gene editing– tag –

  • Biotech Investment

    Biotech Investment News: Vertex’s Major Biotech Deals (2015–2025)

    Strategic Review: From Cystic Fibrosis to Gene Editing and Regenerative Medicine Vertex Pharmaceuticals has leveraged its dominance in cystic fibrosis (CF) treatment to expand into gene editing, regenerative medicine, pain manageme Verte...
    2025-07-01
  • Biotech Investment

    Biotech Investment News: Eli Lilly’s Key Deals from 2015 to 2025

    Strategic Overview: Dominance in Diabetes and Obesity with Oncology Expansion Eli Lilly has strengthened its global leadership in diabetes and obesity while expanding into oncology, neuroscience, and gene therapy. With the blockbuster su...
    2025-06-28
  • Epigenetic Editing Expands the Reach of Gene Therapy: Drug …
    AI Drug Discovery

    Epigenetic Editing Expands the Reach of Gene Therapy: Drug Discovery News Spotlight

    A U.S. research team has demonstrated the therapeutic potential of epigenetic editing — a strategy that regulates gene expression without altering the DNA or RNA sequence itself. Unlike conventional gene editing, this approach employs pr...
    2025-06-16
1
MorningMorning|管理人

創薬の最前線に20年以上。基礎研究から新薬開発、そして投資の側まで――投資家の視点も持ちながら、がん領域を軸に日米欧で歩いてきました。最先端のがん治療・創薬・AI創薬・バイオ投資を、正確に、面白く、毎日お届けします。

▶ もっと詳しく(プロフィール)

▶ X:@MorningGlorySci

コメント・ご質問、お待ちしています。

MorningMorning|Author

20+ years at the frontline of drug discovery — from basic research to development to the investor's side. Oncology-focused, across Japan, the US, and Europe. Cutting-edge cancer therapy, drug discovery, AI drug development, and biotech investment — accurate and engaging, every day.

▶ More (Profile)

▶ X: @MorningGlorySci

Comments & questions welcome.

  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語

© Create the Most Advanced Therapeutics ~ Pharmas, Biotech Ventures, and Investors~.

  • Menu
  • Disclaimer
  • Privacy Policy
  • Sitemap
  • Contact Us
  • 日本語